Follow
Isofol Medical AB
Nasdaq First North Sweden (Sweden)
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. It's products used for increase efficacy and reduce the side effects of antimetabolite cancer treatment.
Sector:
HEALTH CARE
Sector:
TECHNOLOGY
New issue
Price
3.50 SEK
Subscription period
18 May - 01 Jun 2020
View Details
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
ISOFOL
SE0009581051
Nasdaq First North Sweden
Sweden (SE)
Details of share in Isofol Medical AB with ticker ISOFOL
Status
Active
Order book id
Amount of instruments
32 054 802
Par value
0.0300
Market cap
Currency
SEK
Segment
First North Premier
First trading date
04 Apr 2017
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
29.00 SEK
487M SEK
21 Mar - 03 Apr 2017
IPO in Isofol Medical AB
Market
Nasdaq First North Sweden
Subscription period
21 Mar - 03 Apr 2017
Subscription price
29.00 SEK
Price per share
29.00 SEK
Target to raise
430 000 000 SEK
Types
Share issue
Pre-money valuation
487 000 000 SEK
Subscription block size
Minimum subscription
350
Record date
Offer status
Closed
Listing status
Listed
First trading date
04 Apr 2017
Issue terms
Open to the public.
Comments for offer & related information
The company issues 14 828 000shares.

Type
Price
Pre-money valuation
Time
Files
New issue
3.50 SEK
112.19M SEK
18 May - 01 Jun 2020
Share issue in Isofol Medical AB
Market
Nasdaq First North Sweden
Subscription period
18 May - 01 Jun 2020
Subscription price
3.50 SEK
Price per share
3.50 SEK
Target to raise
150 000 000 SEK
Types
Share issue
Pre-money valuation
112 191 807 SEK
Subscription block size
Minimum subscription
Record date
14 May 2020
Offer status
Active
Listing status
Listed
 
Issue terms
Shareholders receive 1 (one) subscription right for each share held on the record date. Three (3) subscription rights entitle to subscription of 4 (four) shares in the Rights Issue.
Comments for offer & related information
An extraordinary general meeting will be held around May 5, 2020 (the “EGM”) where the EGM is proposed to resolve to authorize the Board of Directors to resolve on the Rights Issue. The Rights Issue is fully guaranteed through subscription and guarantee commitments. The subscription price in the Rights Issue and the potential Over-Allotment Option will not exceed SEK 9.
Through the potential Over-Allotment Option, if exercised in full, the Company will receive an additional financing of approximately SEK 30 million before transaction costs. The potential Over-Allotment Option is conditional upon the Rights Issue being oversubscribed.
Update (07.05.2020): The subscription price in the Rights Issue is SEK 3.5 per share, which corresponds to a discount of approximately 36 percent compared with the theoretical price after separation of subscription rights, based on the closing price of the Isofol share on Nasdaq First North Premier Growth Market on May 6, 2020. The Rights Issue is fully guaranteed, including commitments from members of the Board of Directors and Management to subscribe for their pro rata shares amounting to SEK 0.8 million, as well as guarantee commitments from existing shareholders and non-shareholders, including the Chairman of the Board, Pär-Ola Mannefred (through Aktiebolaget Äpplet). The company issues 42 739 736 shares.
In addition to the Rights Issue, the Board of Directors is authorized to exercise the potential Over-Allotment Option, which would provide Isofol with a maximum of approximately SEK 30 million before transaction costs, equal to 8 571 428 over-allotment shares. The Over-Allotment Option can be exercised to meet potential additional demand from strategic investors, thereby broadening Isofol’s shareholder base and is conditional upon the Rights Issue being oversubscribed.
People
Number of Employees
11 people
Anders Rabbe
CEO
Ulf Jungnelius
Chairman of the board
Ulf Jungnelius
Board member
Bengt Gustavsson
Board member
Anders Vedin
Board member
Magnus Björsne
Board member
Paula Boultbee
Board member
Jonas Pedersén
Board member
Alain Herrera
Board member
Company Details
Sector
HEALTH CARE, TECHNOLOGY
Website

Address
Arvid Wallgrens Backe 20 5tr
Zip code
413 46
City/district
Gothenburg
Country
Sweden (SE)
Registration number
556759-8064
LEI code
549300MCXYAHG7VBHX75
First trade date
04 Apr 2017
Registration date
19 Jun 2008
Short name
Isofol Medical

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date